Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Encephalitis ll: Pathophysiology01:26

Encephalitis ll: Pathophysiology

17
Encephalitis is inflammation of the brain parenchyma caused by direct viral invasion or immune-mediated mechanisms triggered by infections or tumors. Both processes lead to neuronal injury, disrupted neurotransmission, and diverse neurological symptoms, often with overlapping clinical and pathological features.Autoimmune EncephalitisIn autoimmune encephalitis, antibodies target neuronal antigens on cell surfaces, synapses, or within neurons. A key example is anti-NMDAR encephalitis, which can...
17
Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

1.7K
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
1.7K
Cerebral Edema ll: Pathophysiology01:22

Cerebral Edema ll: Pathophysiology

11
Vasogenic edema is a major form of cerebral edema characterized by abnormal accumulation of fluid in the brain’s extracellular space due to disruption of the blood–brain barrier (BBB). The BBB is a specialized structure composed of endothelial cells connected by tight junctions, supported by astrocytic endfeet and a basement membrane. Under normal conditions, it tightly regulates the movement of ions, proteins, and solutes between the bloodstream and brain parenchyma. When this...
11
Bacterial Meningitis II: Pathophysiology01:26

Bacterial Meningitis II: Pathophysiology

10
Bacterial meningitis typically begins when pathogens such as Neisseria meningitidis and Streptococcus pneumoniae colonize the nasopharynx and invade the bloodstream. This process is facilitated by bacterial virulence factors, such as polysaccharide capsules, which resist phagocytosis and complement-mediated killing. Less commonly, bacteria reach the central nervous system via contiguous spread from infections like otitis media or sinusitis, through congenital or acquired dural defects, or...
10
Encephalitis l: Introduction01:19

Encephalitis l: Introduction

10
Encephalitis is inflammation of the brain parenchyma, most often due to infections or autoimmune processes. It presents with neuropsychiatric features such as fever, altered mental status, behavioral changes, cognitive dysfunction, seizures, focal deficits, and sometimes autonomic instability. In some cases, the meninges are also involved, resulting in meningoencephalitis.Infectious CausesInfectious encephalitis is most commonly viral but can also result from bacterial, fungal, or parasitic...
10
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

1.7K
γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for...
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Neuroimmunology of Epilepsy: Mechanisms, Treatments, and Clinical Insights.

Epilepsy currents·2026
Same author

Second-Generation of Deuterium-Substituted Glutamate Uptake Enhancers Exhibit Superior Drug-Like Properties in Preclinical Evaluation.

ACS central science·2026
Same author

A staged zebrafish-mouse screening strategy for antiseizure compound prioritization.

Neuropharmacology·2026
Same author

Gut-Brain Axis Modulation by Short-Chain Fatty Acids Exerts Disease-Modifying Effects in a Murine Model of Drug-Resistant Epilepsy.

Annals of neurology·2026
Same author

Assessment of Cell-Type-Specific Excitatory Synaptic Strength in the Dorsolateral Striatum of Goal-Directed and Habitual Cocaine-Seeking Behavior.

eNeuro·2026
Same author

Elevated body temperature affects spike-and-wave discharges and induces behavioural deficits in genetic absence epilepsy rats.

Epilepsy research·2026

Related Experiment Video

Updated: Apr 27, 2026

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

7.7K

Does brain inflammation mediate pathological outcomes in epilepsy?

Karen S Wilcox1, Annamaria Vezzani

  • 1Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, 84108, USA, Karen.wilcox@hsc.utah.edu.

Advances in Experimental Medicine and Biology
|July 12, 2014
PubMed
Summary

Central nervous system (CNS) inflammation, particularly involving the IL-1β system, lowers seizure threshold and contributes to epilepsy. Targeting inflammatory pathways offers potential new treatments for drug-resistant seizures and epileptogenesis.

More Related Videos

Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.3K
Improved 3D Hydrogel Cultures of Primary Glial Cells for In Vitro Modelling of Neuroinflammation
09:19

Improved 3D Hydrogel Cultures of Primary Glial Cells for In Vitro Modelling of Neuroinflammation

Published on: December 8, 2017

14.7K

Related Experiment Videos

Last Updated: Apr 27, 2026

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures
10:05

A Model of Epileptogenesis in Rhinal Cortex-Hippocampus Organotypic Slice Cultures

Published on: March 18, 2021

7.7K
Lipidomics and Transcriptomics in Neurological Diseases
09:58

Lipidomics and Transcriptomics in Neurological Diseases

Published on: March 18, 2022

3.3K
Improved 3D Hydrogel Cultures of Primary Glial Cells for In Vitro Modelling of Neuroinflammation
09:19

Improved 3D Hydrogel Cultures of Primary Glial Cells for In Vitro Modelling of Neuroinflammation

Published on: December 8, 2017

14.7K

Area of Science:

  • Neuroimmunology
  • Epileptology
  • Pharmacology

Background:

  • Inflammation in the central nervous system (CNS) is linked to epilepsy.
  • Increased soluble molecules and receptors in epileptogenic foci modulate neuronal activity.
  • These inflammatory mediators activate pathways in glia and neurons, causing hyperexcitability and seizure generation.

Purpose of the Study:

  • To review recent findings on inflammation's role in epilepsy and epileptogenesis.
  • To explore the potential of targeting inflammatory mediators, especially the IL-1β system, for novel therapies.
  • To discuss preclinical evidence for anti-inflammatory strategies in treating drug-resistant epilepsy.

Main Methods:

  • Review of recent scientific literature and preclinical studies.
  • Analysis of the role of specific inflammatory signaling pathways in seizure generation.
  • Evaluation of therapeutic potential of targeting inflammation in epilepsy models.

Main Results:

  • Inflammation reduces seizure threshold and contributes to seizure generation and epileptogenesis.
  • The IL-1β system is a key inflammatory mediator implicated in epilepsy.
  • Preclinical studies show promise for inhibiting pro-inflammatory signaling to control seizures.

Conclusions:

  • Targeting CNS inflammation presents a promising therapeutic avenue for epilepsy.
  • Pharmacological inhibition of specific inflammatory pathways may treat drug-resistant seizures.
  • Anti-inflammatory approaches could potentially delay or halt epileptogenesis.